Supriya Ghosh


Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Routes of administration  Oral
Biological half-life  6–7 hours
PubChem CID  9828911
Molar mass  546.7036 g/mol
ATC code  None
CAS Number  249921-19-5
ChemSpider  8004650
Anamorelin httpswwwhpcimediacomimageswebsiteManChemNe

Dr abernethy discusses anamorelin as a treatment option for patients with cancer anorexia cachexia

Anamorelin (INN) (developmental code names ONO-7643, RC-1291, ST-1291), also known as anamorelin hydrochloride (USAN, JAN), is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is under development by Helsinn Therapeutics for the treatment of cancer cachexia and anorexia.


Anamorelin significantly increases plasma levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3) in humans, without affecting plasma levels of prolactin, cortisol, insulin, glucose, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH). In addition, anamorelin significantly increases appetite, overall body weight, lean body mass, and muscle strength, with increases in body weight correlating directly with increases in plasma IGF-1 levels.

As of February 2016, anamorelin has completed phase III clinical trials for the treatment of cancer cachexia and anorexia associated with non-small-cell lung carcinoma. Results of the studies were positive, and the drug is now in preregistration with the European Medicines Agency.[1]

Dr temel discusses her work on anamorelin for treating nsclc patients with anorexia and cachexia


Anamorelin Wikipedia

Similar Topics
The Photographical Congress Arrives in Lyon
Annemarie Biechl
Anđelko Ćuk